Search
Technology use, including continuous glucose monitoring (CGM) and insulin pump therapy, is associated with improved outcomes in youth with type 1 diabetes (T1D). In 2017 CGM was universally funded for youth with T1D in Australia. In contrast, pump access is primarily accessed through private health insurance, self-funding or philanthropy.
In Australia, access to insulin pump therapy for children with type 1 diabetes is predominantly restricted to families with private health insurance. In an attempt to improve equity, additional subsidised pathways exist which provide pumps to families with reduced financial resources. We aimed to describe the outcomes and experiences of families with children commenced on pumps through these subsidised pathways in Western Australia.
Type 1 diabetes is well-recognised as a continuum heralded by the development of islet autoantibodies, progression to islet autoimmunity causing beta cell destruction, culminating in insulin deficiency and clinical disease. Abnormalities of glucose homeostasis are known to exist well before the onset of typical symptoms.
We sought research experiences of caregivers and their children were enrolled in the Environmental Determinants of Islet Autoimmunity (ENDIA) study.
Besides the challenges associated with their teenage years, adolescents with Type 1 Diabetes (T1D) encounter additional challenges of having a chronic condition.
See an overview of the people involved in the Children's Diabetes Centre, including co-directors, research focus area leads, research staff and students
Our Centre is involved with a wide range of research projects, many involving collaborating with partners to run trials of new technologies and treatments.
The Children's Diabetes Centre provides student opportunities for integrated research and clinical projects across all our research areas.
Our researchers are trying to learn more about the effect different types of food have on blood glucose levels and how to give the best insulin dose to manage a variety of foods.